Studienpraxis Urologie

Nürtingen 72622

3 studies enrolling now · 17 studies all time

What they study most

Bladder Cancer, Carcinoma, Transitional Cell, Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Urothelial Carcinoma, Muscle Invasive Bladder Cancer, Neoplasm Metastasis, Non-muscle Invasive Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Running, not enrolling
• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed
• PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) — Stopped early
• ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer — Completed
• A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer — Completed
• Derazantinib and Atezolizumab in Patients With Urothelial Cancer — Completed
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma — Stopped early
• A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency — Completed
• Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer — Running, not enrolling
• Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer — Completed